Management of Brain Tumor Treatment with Tumor Morphometrics in Magnetic Resonanc

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$200,619.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA128188-01
Agency Tracking Number:
CA128188
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
PRISM CLINICAL IMAGING INC.
PRISM CLINICAL IMAGING, INC., 851 S. 70th St., Suite 103, West Allis, WI, 53214
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
190899638
Principal Investigator:
JAMES REUSS
(414) 727-1930
JAMESREUSS@KYRONCLINICAL.COM
Business Contact:
MICHAEL SCHMAINDA
() -
jreuss@prismclinical.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Radiology has traditionally relied upon qualitative assessment of tumor growth to guide therapeutic decision-making. The adoption of quantitative techniques such as WHO and RECIST guidelines in radiology has been slow due to multiple factors, including the workload and inter-operator variability associated with manual measurement, the complexity and pitfalls of automated techniques, and the many inherent sources of variability in medical imaging making longitudinal comp arison difficult. We will develop, design and evaluate a semi- automated morphometrics system for quantification of tumors in the brain. The input to our system will be multiple images from magnetic resonance imaging (MRI) systems, particularly post-contra st T1 studies. The final product will be a modular extension to our FDA-cleared Prism View(tm) software package, compatible with MRI systems currently used for brain imaging. We will demonstrate feasibility in Phase I by developing means for geometrical re gistration and intensity standardization in imaging protocols, collecting data to document intra-patient and intra- and inter-reader variability, and evaluating our system in a study of a small number of subjects. In Phase II, we will further refine algori thms based upon Phase I findings and evaluate our system in a much larger cohort of subjects to more rigorously evaluate accuracy and precision in sizing of tumors. If successful, greater confidence will be achieved in following tumor changes over time, an d this should translate into more rapid understanding of the efficacy of medical treatment or management of brain tumors. Our focus is on 2D and 3D tumor geometry, not on tumor composition. However, the existing product line (Prism) already facilitates com bination and viewing of functional and physiologic information including MR spectroscopy and MR perfusion studies, and this information will be readily superposed upon the regions of interest delineated in anatomical imagery.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government